Date of Abstract presentation9th December 2023
IndicationsChronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
Abstract Number330
Abstract typeOral

TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) after progression on a BTK inhibitor (BTKi) and BCL-2 inhibitor (BCL2i). The study included a broad population of patients with relapsed or refractory CLL or SLL with high unmet need who had received at least two prior lines of therapy, including a BTKi (n=118), to be treated with BREYANZI. According to the findings presented at the ASH 2023 conference, the sustained undetectable minimal residual disease (uMRD) rates with BREYANZI persisted in the long-term follow-up, showing an uMRD rate of 64% in blood and 60% in bone marrow. The overall response rate (ORR) increased to 44%, with a median duration of response (DOR) of 35.3 months. Notably, one patient initially responding partially achieved a complete response (CR) without additional therapy at 18 months. Among 9 patients with CR at the primary analysis, 8 maintained ongoing CRs, and one completed the study with the last assessment as a CR. Furthermore, the U.S. Food and Drug Administration (US FDA) is currently reviewing a supplemental Biologics License Application (BLA) for Breyanzi in the treatment of relapsed or refractory CLL, with results derived from the TRANSCEND CLL 004 study. The anticipated action date for this application is set for March 14, 2024.

Regarding safety, BREYANZI demonstrated a well-tolerated safety profile in the entire treated patient cohort (n=118). Notably, 85% of patients experienced any grade cytokine release syndrome (CRS), with 8% experiencing Grade 3 CRS and no occurrences of Grade 4/5 CRS. Neurologic events (NEs) were reported in 45% of patients, including 18% with Grade 3 NEs, 1% with Grade 4 NEs, and no instances of Grade 5 NEs.

KOL Insights

“For patients with relapsed or refractory CLL, current treatment options rarely provide complete responses, and durability of response is limited. With long-term follow-up from TRANSCEND CLL 004, the complete and lasting responses achieved with liso-cel are unprecedented in this patient population, with a deepening of responses observed over time and a manageable and predictable safety profile. Based on these results, liso-cel has the potential to be a significant advance in the treatment of relapsed or refractory CLL.”–Expert Opinion.


With extended monitoring from TRANSCEND CLL 004, the sustained complete responses achieved with liso-cel set a new standard in this patient cohort, demonstrating deepening responses over time and maintaining a manageable and expected safety profile. These findings position liso-cel as a potentially groundbreaking advancement in the management of relapsed or refractory chronic lymphocytic leukemia (CLL).

Refer to the Related Reports for More In-depth Insights